Oncogene最新文献

筛选
英文 中文
MAZ promotes tumor proliferation and immune evasion in lung adenocarcinoma MAZ 可促进肺腺癌的肿瘤增殖和免疫逃避。
IF 6.9 1区 医学
Oncogene Pub Date : 2024-10-18 DOI: 10.1038/s41388-024-03194-y
Yan Chen, Xinsheng Zhu, Jue Wang, Junjie Hu, Jing Zhang, Xun Zhang, Lu Han, Huansha Yu, Haiyang Hu, Ke Fei, Peng Zhang, Lele Zhang
{"title":"MAZ promotes tumor proliferation and immune evasion in lung adenocarcinoma","authors":"Yan Chen, Xinsheng Zhu, Jue Wang, Junjie Hu, Jing Zhang, Xun Zhang, Lu Han, Huansha Yu, Haiyang Hu, Ke Fei, Peng Zhang, Lele Zhang","doi":"10.1038/s41388-024-03194-y","DOIUrl":"10.1038/s41388-024-03194-y","url":null,"abstract":"Lung adenocarcinoma (LUAD) is the most dominant histological subtype of lung cancer and one of the most lethal malignancies. The identification of novel therapeutic targets is required for the treatment of LUAD. Here, we showed that MYC-associated zinc-finger protein (MAZ) is upregulated in LUAD tissues. MAZ expression levels are inversely correlated with patient survival. Silencing of MAZ decreased tumor proliferation and the expression of pro-tumorigenic chemokines and Galectin-9 (Gal-9), an immune checkpoint molecule. The pro-tumorigenic chemokines and Gal-9 induce immune suppression by recruitment of myeloid cells and inhibition of T cell activation, respectively. Mechanistically, MAZ transcriptionally regulates KRAS expression and activates its downstream AKT-NF-κB signaling pathway, which is crucial for tumor progression and immune evasion. Additionally, in vivo animal models and bioinformatic analyses indicated that MAZ suppression could enhance the efficacy of immune checkpoint blockade (ICB) therapy for LUAD. Overall, our results suggest that MAZ plays an important role in regulating cell proliferation and immune evasion via KRAS/AKT/NF-κB signaling in LUAD. Our findings offer a candidate molecular target for LUAD therapy, with implications for improving the efficacy of ICB therapy.","PeriodicalId":19524,"journal":{"name":"Oncogene","volume":"43 50","pages":"3619-3632"},"PeriodicalIF":6.9,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41388-024-03194-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142471604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Obesity-induced extracellular vesicles proteins drive the endometrial cancer pathogenesis: therapeutic potential of HO-3867 and Metformin 肥胖诱导的细胞外囊泡蛋白驱动子宫内膜癌发病机制:HO-3867 和二甲双胍的治疗潜力
IF 6.9 1区 医学
Oncogene Pub Date : 2024-10-16 DOI: 10.1038/s41388-024-03182-2
Takahiko Sakaue, Kalpana Deepa Priya Dorayappan, Roman Zingarelli, Wafa Khadraoui, Muralidharan Anbalagan, John Wallbillich, Balazs Bognar, Ross Wanner, Casey Cosgrove, Adrian Suarez, Hironori Koga, G. Larry Maxwell, David M. O’Malley, David E. Cohn, Karuppaiyah Selvendiran
{"title":"Obesity-induced extracellular vesicles proteins drive the endometrial cancer pathogenesis: therapeutic potential of HO-3867 and Metformin","authors":"Takahiko Sakaue, Kalpana Deepa Priya Dorayappan, Roman Zingarelli, Wafa Khadraoui, Muralidharan Anbalagan, John Wallbillich, Balazs Bognar, Ross Wanner, Casey Cosgrove, Adrian Suarez, Hironori Koga, G. Larry Maxwell, David M. O’Malley, David E. Cohn, Karuppaiyah Selvendiran","doi":"10.1038/s41388-024-03182-2","DOIUrl":"10.1038/s41388-024-03182-2","url":null,"abstract":"Endometrial cancer (EC) is the leading gynecologic malignancy in the United States with obesity implicated in 57% of cases. This research investigates the molecular complexities of extracellular vesicles (EV) secretion as carriers of oncogenic protein and their involvement in obesity-mediated EC. An understanding of these mechanisms is pivotal for unraveling pathways relevant to obesity-associated EC, thereby guiding the development of innovative prevention and treatment strategies. Our exploration revealed a significant increase in EV secretion carrying oncogenic proteins (TMEM205, STAT5, and FAS) in adipose and uterine tissues/serum samples from obese EC patients compared to control (without cancer). We identified alterations in EV-regulating proteins (Rab7, Rab11, and Rab27a) in obesity-mediated EC patients, adipose/uterine tissues, and serum samples. Through a 24-week analysis of the effects of a 45% kcal high-fat diet (HFD) on mice, we observed increased body weight, increased adipose tissue, enlarged uterine horns, and increased inflammation in the HFD group. This correlated with elevated levels of EV secretion and increased expression of oncogenic proteins TMEM205, FAS, and STAT5 and downregulation of the tumor suppressor gene PIAS3 in adipose and uterine tissues. Furthermore, our study confirmed that adipocyte derived EV increased EC cell proliferation, migration and xenograft tumor growth. Additionally, we identified that the small molecule inhibitors (HO-3867) or Metformin inhibited EV secretion in vitro and in vivo, demonstrating significant inhibition of high glucose or adipocyte-mediated EC cell proliferation and a reduction in body weight and adipose tissue accumulation when administered to HFD mice. Moreover, HO-3867 or Metformin treatment inhibited HFD induced hyperplasia (precursor of EC) by altering the expression of EV-regulated proteins and decreasing oncogenic protein expression levels. This study provides critical insights into the mechanisms underpinning obesity-mediated EV secretion with oncogenic protein expression, shedding light on their role in EC pathogenesis. Additionally, it offers pre-clinical evidence supporting the initiation of novel studies for EV-targeted therapies aimed at preventing obesity-mediated EC.","PeriodicalId":19524,"journal":{"name":"Oncogene","volume":"43 49","pages":"3586-3597"},"PeriodicalIF":6.9,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41388-024-03182-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142471607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mesenchymal stromal cells as cancer promoters 间充质基质细胞是癌症的促进因素。
IF 6.9 1区 医学
Oncogene Pub Date : 2024-10-16 DOI: 10.1038/s41388-024-03183-1
Roula Antoon, Nina Overdevest, Amr H. Saleh, Armand Keating
{"title":"Mesenchymal stromal cells as cancer promoters","authors":"Roula Antoon, Nina Overdevest, Amr H. Saleh, Armand Keating","doi":"10.1038/s41388-024-03183-1","DOIUrl":"10.1038/s41388-024-03183-1","url":null,"abstract":"Mesenchymal stromal cells (MSCs) are important cellular constituents of tumor stroma that play an active role in tumor development. Complex interactions between MSCs and cancer promote tumor progression by creating a favorable milieu for tumor cell proliferation, angiogenesis, motility, invasion, and metastasis. The cellular heterogeneity, source of origin, diversity in isolation methods, culture techniques and model systems of MSCs, together with the different tumor subtypes, add to the complexity of MSC-tumor interactions. In this review, we discuss the mechanisms of MSC-mediated tumor promotion and evaluate cell-stromal interactions between cancer cells, MSCs, cells of the tumor microenvironment (TME), and the extracellular matrix (ECM). A more thorough understanding of tumor-MSC interactions is likely to lead to better cancer management.","PeriodicalId":19524,"journal":{"name":"Oncogene","volume":"43 49","pages":"3545-3555"},"PeriodicalIF":6.9,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41388-024-03183-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142471605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NEU4-mediated desialylation enhances the activation of the oncogenic receptors for the dissemination of ovarian carcinoma NEU4 介导的脱ialylation 可增强卵巢癌扩散过程中致癌受体的激活。
IF 6.9 1区 医学
Oncogene Pub Date : 2024-10-14 DOI: 10.1038/s41388-024-03187-x
Jie Shi, Rui Zhou, Shuo Wang, Yuxin Liu, Baorui Tian, Yanhua Liu, Yanan Chen, Taoyu Hu, Yuhao Mu, Shufan Wang, Xintao Shao, Jie Yan, Pengpeng Qu, Ding Wei, Shuang Yang, Yi Shi, Jia Li, Longlong Wang
{"title":"NEU4-mediated desialylation enhances the activation of the oncogenic receptors for the dissemination of ovarian carcinoma","authors":"Jie Shi, Rui Zhou, Shuo Wang, Yuxin Liu, Baorui Tian, Yanhua Liu, Yanan Chen, Taoyu Hu, Yuhao Mu, Shufan Wang, Xintao Shao, Jie Yan, Pengpeng Qu, Ding Wei, Shuang Yang, Yi Shi, Jia Li, Longlong Wang","doi":"10.1038/s41388-024-03187-x","DOIUrl":"10.1038/s41388-024-03187-x","url":null,"abstract":"Glycosylation profoundly influences the interactions between cancer cells and microenvironmental stromal cells during the peritoneal disseminated metastasis of ovarian carcinoma (OC), which is the major cause of cancer-related death. Although the characteristic cancer glycoconjugates are widely used as biomarkers for cancer diagnosis, our knowledge about cancer glycome remains quite fragmented due to the technique limitations in analyzing glycan chains with tremendous structural and functional heterogeneity. Given the dysregulated cancer glycome is defined by the altered glycosylation machinery, here we performed a systematic loss-of-function screen on 498 genes involved in glycosylation for key regulators of OC dissemination. We identified neuraminidase 4 (NEU4), an enzyme capable of hydrolyzing terminal sialic acid from glycoconjugates, as a vital peritoneal dissemination-promoting modifier of OC glycome. In human patients with high-grade serous OC (HGSOC), increased NEU4 was detected in the disseminated OC cells when compared with that in the primary tumor cells, which significantly correlated with the worse survival. Among three alternative splice-generated isoforms of human NEU4, we revealed that only the plasma membrane-localized NEU4 isoform 2 (NEU4-iso2) and intracellular isoform 3 promoted the peritoneal dissemination of OC by enhancing the cell motility and epithelial-mesenchymal transition. We also identified NEU4-iso2-regulated cell surface glycoproteome and found that NEU4-iso2 desialylated the epithelial growth factor receptor (EGFR), in particular at N196 residue, for the hyperactivation of EGFR and its downstream tumor-promoting signaling cascades. Our results provide new insights into how the OC glycome is dysregulated during OC progression and reveal a functionally important glycosite on EGFR for its abnormal activation in cancer.","PeriodicalId":19524,"journal":{"name":"Oncogene","volume":"43 49","pages":"3556-3569"},"PeriodicalIF":6.9,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41388-024-03187-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142471606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CypA/TAF15/STAT5A/miR-514a-3p feedback loop drives ovarian cancer metastasis CypA/TAF15/STAT5A/miR-514a-3p反馈回路驱动卵巢癌转移。
IF 6.9 1区 医学
Oncogene Pub Date : 2024-10-14 DOI: 10.1038/s41388-024-03188-w
Ying Li, Huiwen Yang, An Li, Buze Chen, Yue Wang, Ziwei Song, Haozhou Tan, Hui Li, Qian Feng, Yuan Zhou, Shibao Li, Lingyu Zeng, Ting Lan
{"title":"CypA/TAF15/STAT5A/miR-514a-3p feedback loop drives ovarian cancer metastasis","authors":"Ying Li, Huiwen Yang, An Li, Buze Chen, Yue Wang, Ziwei Song, Haozhou Tan, Hui Li, Qian Feng, Yuan Zhou, Shibao Li, Lingyu Zeng, Ting Lan","doi":"10.1038/s41388-024-03188-w","DOIUrl":"10.1038/s41388-024-03188-w","url":null,"abstract":"Cyclophilin A (CypA) is a peptidyl-prolyl isomerase that participates in multiple cancer events, but the molecular mechanisms of abnormal expression and regulation of CypA in ovarian cancer (OC) have never been considered. This study identifies CypA as a key driver of epithelial-mesenchymal transition (EMT) in ovarian cancer and explores the mechanisms that underly this process. We show that CypA is upregulated in tissues and serum of ovarian cancer patients and that CypA overexpression correlates with poor prognosis. CypA facilitates tumor growth and metastasis in vivo in subcutaneous tumor xenograft and abdominal metastatic models, and in vitro studies suggest a mechanism, showing that CypA accelerates ovarian cancer cell epithelial-mesenchymal transition by activating a PI3K/AKT signaling pathway. Mechanistic studies showed that STAT5A binds pri-miR-514a-3p and inhibits its activity, whereas miR-514a-3p directly binds to the 3ʹ-UTR of CypA to suppress its expression, resulting in STAT5A promoting the expression of CypA, forming the STAT5A/miR-514a-3p/CypA axis. Furthermore, immunoprecipitates and mass spectrometry analysis identifies a CypA interaction with TAF15 that stabilizes TAF15 by suppressing its proteasome degradation and promotes its entry into the nucleus. While STAT5A is positively regulated by TAF15. Our findings identify a novel feedback loop for CypA that drives EMT and ovarian tumor growth and metastasis via a TAF15/STAT5A/miR-514a-3p pathway in ovarian cancer and facilitates the release of CypA into the extracellular, which provides a promising therapeutic target for OC treatment and a diagnostic biomarker.","PeriodicalId":19524,"journal":{"name":"Oncogene","volume":"43 49","pages":"3570-3585"},"PeriodicalIF":6.9,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142471602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aberrant FAM135B attenuates the efficacy of chemotherapy in colorectal cancer by modulating SRSF1-mediated alternative splicing 异常的 FAM135B 通过调节 SRSF1 介导的替代剪接来削弱结直肠癌化疗的疗效。
IF 6.9 1区 医学
Oncogene Pub Date : 2024-10-13 DOI: 10.1038/s41388-024-03189-9
Wanmei Lin, Lijun Xu, Yaoying Li, Junze Li, Liang Zhao
{"title":"Aberrant FAM135B attenuates the efficacy of chemotherapy in colorectal cancer by modulating SRSF1-mediated alternative splicing","authors":"Wanmei Lin, Lijun Xu, Yaoying Li, Junze Li, Liang Zhao","doi":"10.1038/s41388-024-03189-9","DOIUrl":"10.1038/s41388-024-03189-9","url":null,"abstract":"Oxaliplatin is the frontline chemotherapy drug for the treatment of colorectal cancer (CRC) and its insensitivity is a major limitation on therapeutic efficacy. Genomic instability is the prominent feature of CRC and is considered to correlate with response to treatments. However, the underlying mechanism of insensitivity to oxaliplatin (L-OHP) remains largely unclear. Herein, sequence similarity 135 family member B (FAM135B) is identified as a frequently mutated gene in CRC and is critical for CRC proliferation and impaired response to L-OHP by controlling SRSF1-mediated alternative splicing. Specifically, FAM135B promotes the nuclear translocation of SRSF1 by synergistically binding with SRPK1 and regulates SRSF1-mediated splicing of DNA repair genes. FAM135B-induced exon IV inclusion of FAAP20 mediates its binding with FACNA and enhances the functional integrity of the FA core complex, thereby activating the FA pathway and resulting in inter-strand crosslink (ICL) lesion repair and L-OHP insensitivity. These findings reveal that the FAM135B-SRSF1 axis-mediated splicing contributes to DNA repair and chemotherapeutic insensitivity in CRC. Targeting FAM135B represents a potential strategy for CRC treatment.","PeriodicalId":19524,"journal":{"name":"Oncogene","volume":"43 48","pages":"3532-3544"},"PeriodicalIF":6.9,"publicationDate":"2024-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41388-024-03189-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142471601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The methionine cycle and its cancer implications 蛋氨酸循环及其对癌症的影响。
IF 6.9 1区 医学
Oncogene Pub Date : 2024-10-11 DOI: 10.1038/s41388-024-03122-0
Valentina Tassinari, Wei Jia, Wen-Lian Chen, Eleonora Candi, Gerry Melino
{"title":"The methionine cycle and its cancer implications","authors":"Valentina Tassinari, Wei Jia, Wen-Lian Chen, Eleonora Candi, Gerry Melino","doi":"10.1038/s41388-024-03122-0","DOIUrl":"10.1038/s41388-024-03122-0","url":null,"abstract":"The essential amino acid methionine is a crucial regulator of sulfur metabolism in a variety of interconnected biochemical pathways. The methionine cycle is intricately linked to the folate cycle, forming the one-carbon metabolism, a crucial regulator of S-adenosylmethionine, SAM. Recent work highlights methionine’s critical role in tumor growth and progression, maintaining polyamine synthesis, and playing a crucial role in the regulation of SAM both in altered chromatin states, depending on p53 status, as well as facilitating m6A methylation of NR4A2 mRNA, hence regulating proliferation in esophageal carcinoma. Accordingly, Celecoxib, a specific NR4A2 inhibitor, is a potentially powerful inhibitor of tumor growth at least in this specific model. Additionally, formaldehyde, from endogenous or exogenous sources, can directly regulate both SAM steady-state-levels and the one-carbon metabolism, with relevant implication in cancer progression. These recent scientific advancements have provided a deeper understanding of the molecular mechanisms involved in cancer development, and its potential therapeutic regulation.","PeriodicalId":19524,"journal":{"name":"Oncogene","volume":"43 48","pages":"3483-3488"},"PeriodicalIF":6.9,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41388-024-03122-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GLTSCR1 deficiency promotes colorectal cancer development through regulating non-homologous end joining GLTSCR1 缺乏会通过调节非同源末端连接促进结直肠癌的发展。
IF 6.9 1区 医学
Oncogene Pub Date : 2024-10-11 DOI: 10.1038/s41388-024-03179-x
Fengyan Han, Xiaoxu Zhou, Lu Liu, Beibei Yang, Pengyuan Liu, Enping Xu, Zhe Tang, Honghe Zhang
{"title":"GLTSCR1 deficiency promotes colorectal cancer development through regulating non-homologous end joining","authors":"Fengyan Han, Xiaoxu Zhou, Lu Liu, Beibei Yang, Pengyuan Liu, Enping Xu, Zhe Tang, Honghe Zhang","doi":"10.1038/s41388-024-03179-x","DOIUrl":"10.1038/s41388-024-03179-x","url":null,"abstract":"Non-homologous end joining (NHEJ), as one major pathway of DNA double-strand break (DSB) repair, could cause genomic instability, which plays pivotal roles in cancer development. While, chromatin remodeling complexes dictate the selection and orchestration of DSB repair pathways by regulating chromatin dynamics. However, the crosstalk between NHEJ and chromatin remodeling in cancer progress remains unclear. In this study, deficiency of GLTSCR1 causes resistance to DNA damage in colorectal cancer (CRC) cells by promoting NHEJ repair efficiency. Mechanistically, GLTSCR1 interacts with BRD9 to engage in the assembly of the non-canonical BAF complex (GBAF). However, GLTSCR1 deficiency disrupts GBAF and triggers the ubiquitination degradation of BRD9. Furthermore, GLTSCR1 deficiency causes aberrant opening in the promoter region of NHEJ repair-associated genes, which promotes CRC development. While, GLTSCR1 and its binding partner BRD9 are not directly involved in assembling NHEJ repair machinery; instead, they regulate the DNA accessibility of NHEJ repair-associated genes. Collectively, our findings confirm GLTSCR1 deficiency as a critical regulatory event of the NHEJ pathway in CRC development, which might require different therapeutic strategy for GLTSCR1 wild-type and mutant CRC.","PeriodicalId":19524,"journal":{"name":"Oncogene","volume":"43 48","pages":"3517-3531"},"PeriodicalIF":6.9,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
m6A-driven NAT10 translation facilitates fatty acid metabolic rewiring to suppress ferroptosis and promote ovarian tumorigenesis through enhancing ACOT7 mRNA acetylation m6A 驱动的 NAT10 翻译通过增强 ACOT7 mRNA 乙酰化促进脂肪酸代谢重构,从而抑制铁变态反应并促进卵巢肿瘤发生。
IF 6.9 1区 医学
Oncogene Pub Date : 2024-10-10 DOI: 10.1038/s41388-024-03185-z
Yujiao Liu, Jia Li, Jie Xu, Yingfei Long, Yuan Wang, Xiaoyi Liu, Junchi Hu, Qinglv Wei, Qingya Luo, Fatao Luo, Fengjiang Qin, Qihua Yi, Yu Yang, Yongjun Dang, Jing Xu, Tao Liu, Ping Yi
{"title":"m6A-driven NAT10 translation facilitates fatty acid metabolic rewiring to suppress ferroptosis and promote ovarian tumorigenesis through enhancing ACOT7 mRNA acetylation","authors":"Yujiao Liu, Jia Li, Jie Xu, Yingfei Long, Yuan Wang, Xiaoyi Liu, Junchi Hu, Qinglv Wei, Qingya Luo, Fatao Luo, Fengjiang Qin, Qihua Yi, Yu Yang, Yongjun Dang, Jing Xu, Tao Liu, Ping Yi","doi":"10.1038/s41388-024-03185-z","DOIUrl":"10.1038/s41388-024-03185-z","url":null,"abstract":"RNA epigenetic modifications have been implicated in cancer progression. However, the interplay between distinct RNA modifications and its role in cancer metabolism remain largely unexplored. Our study demonstrates that N-acetyltransferase 10 (NAT10) is notably upregulated in ovarian cancer (OC), correlating with poor patient prognosis. IGF2BP1 enhances the translation of NAT10 mRNA in an m6A-dependent manner in OC cells. NAT10 drives tumorigenesis by mediating N4-acetylcytidine (ac4C) modification of ACOT7 mRNA, thereby augmenting its stability and translation. This NAT10-ACOT7 axis modulates fatty acid metabolism in cancer cells and promotes tumor progression by suppressing ferroptosis. Additionally, our research identifies fludarabine as a small molecule inhibitor targeting NAT10, inhibits the ac4C modification and expression of ACOT7 mRNA. By using cell derived xenograft model and patient derived organoid model, we show that fludarabine effectively suppresses ovarian tumorigenesis. Overall, our study highlights the pivotal role of the NAT10-ACOT7 axis in the malignant cancer progression, underscoring the potential of targeting NAT10-mediated ac4C modification as a viable therapeutic strategy for this disease.","PeriodicalId":19524,"journal":{"name":"Oncogene","volume":"43 48","pages":"3498-3516"},"PeriodicalIF":6.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhibition and degradation of NRAS with a pan-NRAS monobody 用泛 NRAS 单体抑制和降解 NRAS。
IF 6.9 1区 医学
Oncogene Pub Date : 2024-10-08 DOI: 10.1038/s41388-024-03186-y
Michael Whaby, Gayatri Ketavarapu, Akiko Koide, Megan Mazzei, Mubashir Mintoo, Eliezra Glasser, Unnatiben Patel, Cecile Nasarre, Matthew J. Sale, Frank McCormick, Shohei Koide, John P. O’Bryan
{"title":"Inhibition and degradation of NRAS with a pan-NRAS monobody","authors":"Michael Whaby, Gayatri Ketavarapu, Akiko Koide, Megan Mazzei, Mubashir Mintoo, Eliezra Glasser, Unnatiben Patel, Cecile Nasarre, Matthew J. Sale, Frank McCormick, Shohei Koide, John P. O’Bryan","doi":"10.1038/s41388-024-03186-y","DOIUrl":"10.1038/s41388-024-03186-y","url":null,"abstract":"The RAS family GTPases are the most frequently mutated oncogene family in human cancers. Activating mutations in either of the three RAS isoforms (HRAS, KRAS, or NRAS) are found in nearly 20% of all human tumors with NRAS mutated in ~25% of melanomas. Despite remarkable advancements in therapies targeted against mutant KRAS, NRAS-specific pharmacologics are lacking. Thus, development of inhibitors of NRAS would address a critical unmet need to treating primary tumors harboring NRAS mutations as well as BRAF-mutant melanomas, which frequently develop resistance to clinically approved BRAF inhibitors through NRAS mutation. Building upon our previous studies with the monobody NS1 that recognizes HRAS and KRAS but not NRAS, here we report the development of a monobody that specifically binds to both GDP and GTP-bound states of NRAS and inhibits NRAS-mediated signaling in a mutation-agnostic manner. Further, this monobody can be formatted into a genetically encoded NRAS-specific degrader. Our study highlights the feasibility of developing NRAS selective inhibitors for therapeutic efforts.","PeriodicalId":19524,"journal":{"name":"Oncogene","volume":"43 48","pages":"3489-3497"},"PeriodicalIF":6.9,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41388-024-03186-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142392133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信